PNC-27

PNC-27

PNC-27

ʻO PNC-27 kahi peptide anti-cancer i manaʻo nui ʻia.

Pane wikiwiki

Reliable PNC-27 peptide provided by professional manufacturer and factory. Offer wholesale HDM-2 binding anticancer peptides for tumor mechanism research and biomedical laboratory scientific projects.

SKU: 198871 Māhele:
Kaʻana like i kāu aloha

ʻO PNC-27 kahi peptide anti-cancer i manaʻo nui ʻia.

Kāohi ia i ka hoʻopaʻa ʻana ma waena o ka protein suppressor tumor p53 a me kona hooponopono kino HDM-2.

HDM-2, he E3 ubiquitin ligase, paipai i ka ubiquitin mediated degradation ma ka hoʻopaʻa ʻana iā p53.

ʻO nā pūnaewele maʻi maʻi no laila e pale aku i ka ulu ʻana e pili ana a me ka maʻamau apoptosis nā pōʻaiapuni.

Hoʻohālike ka PNC-27 i ka māhele kumu o ka protein p53 (nā ʻakika amino 12-26) iho, e pili ana me kēia HDM-2.

ʻIke ʻia, Loaʻa i ka PNC-27 kahi ʻāpana kūʻokoʻa i waiwai nā ʻakika amino kumu, e kōkua ana i ke komo ʻana o nā membrane cell i makemake nui ʻia.

Kaʻina

H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg

Helu CAS

1159861-00-3

ʻĀpana Molekala

C188H293N53O44S

Kaumaha Molekala

4031.7990

Noiʻi o PNC-27

1.Mechanism of Action and Membrane Disruption

ʻO ka hoʻokuʻu ʻana i kēia paʻa e hiki ai ke hoʻihoʻi piha i ka hana protein p53; ʻO ka hoʻoponopono piha ʻana o nā hana maʻi maʻi maʻi ma kahi pae genetic, ʻO ka hoʻopau ʻana i nā ʻano maʻi āpau ka hopena.

ʻO ka hoʻokuʻu ʻana o ka p53 a laila keʻakeʻa i ka hana ʻana o nā cell cancer, ʻO ka apoptosis pololei kekahi o nā hopena hopena.

Ua nānā ʻia nā haʻawina ma hope i ke ʻano o loko o ka PNC-27 e kāohi ana i nā maʻi maʻi maʻi i loko o nā cell.

Ua hōʻike ʻia ka noiʻi i ka hoʻopau pololei ʻana i ka membrane plasma o ke kanesa – wikiwiki, kokoke ka make hiki ole ke hoohuliia, me ka liʻiliʻi loa a ʻaʻohe hopena i koe ma nā pūnaewele maʻamau.

ʻO ka hoʻopaʻa ʻana iā HDM-2 alakaʻi i ka PNC-27 (ma ka hapa iki) e hoololi i ke ano.

Oligomerization a ua manaʻo ʻia ʻo ka hoʻokumu ʻana i ka pore ka hana hope loa o kēia kaʻina hana.

2.Hoʻopaʻa kikoʻī

ʻO ka ʻike kikoʻī a kiʻekiʻe loa o ka HDM-2 e PNC-27 ka mea e hoʻokō pono ai kēia peptide..

ʻO ka hoʻokuʻu ʻana i ka hana p53 ka pahuhopu mua a me ke kikowaena o ka mīkini holoʻokoʻa.

3.Pepehi koho i na ma'i ma'i ma'i

Hoʻopili paʻa ʻia ka PNC i ka HDM-2 i hōʻike ʻole ʻia ma nā maʻi kanesa, ka hoʻoulu ʻana o ka osmotic imbalance a me ka hemo ʻana o ka membrane.

ʻO kēia ka hopena e alakaʻi ai i ka pehu cell; Loa'a ka make ma'i 'a'ai pololei ma o ka hiki 'ole ke ho'ololi, mīkini wikiwiki.

ʻIke ʻia, Hōʻike nā membrane cell maʻamau i nā ʻāpana liʻiliʻi o kēia HDM-2, no laila, ʻaʻole pili nā cell olakino.

ʻO ka hoʻohaunaele kino o ka membrane cell ponoʻī ka mea e hiki ai i kēia pepehi pololei – ʻO nā ala e hilinaʻi nei i ka p53-mediated intracellular apoptosis hōʻailona ua kaʻawale loa mai kēia kaʻina hana.

Me ka nānā ʻole i ke kūlana o ka gene p53 o ka maʻi kanesa (ʻano ʻāhiu, hoʻololi ʻia, a i ʻole i hoʻohana ʻia), ʻoiai ke ʻike ʻia ka hōʻike HDM-2 ma ka membrane, E hoʻopau pono ʻo PNC-27 iā ia.

Hiki ke hoʻopaʻa ʻia i nā maʻi kanesa, ʻo ka poʻe i hoʻomohala i ke kū'ē i ka chemotherapy maʻamau a me nā ʻano like ʻole o ka radiotherapy; ʻO ka p53 dysfunction ke kumu nui o ia kū'ē.

Ke wehe ʻia nei kahi hoʻolālā lapaʻau hou no nā maʻi maʻi kūʻē i ka mālama ʻana e kēia ʻano hana ʻokoʻa.

COA

HPLC

MS

(1) Pincus, M. R.; Silberstein, M.; Zohar, N.; Sarafraz-Yazdi, E.; Bowne, Ua ʻōlelo ʻo W. B. Poptosis a i ʻole Peptide-Induced Transmembrane Pore Formation: ʻO kahi ala hou e pepehi ai i nā maʻi maʻi maʻi me ka hoʻopilikia ʻole ʻana i nā maʻi maʻamau. Nā lāʻau lapaʻau biomedicine 2024, 12 (6). DOI: 10.3390/biomedicines12061144 Mai NLM PubMed-not-MEDLINE.

(2) ʻO Rosal, R.; Pincus, M. R.; Brandt-Rauf, P. Ua ʻōlelo ʻo W.; Maikaʻi, R. L.; Michl, J.; ʻO Wang, H. ʻO ka hoʻolālā hoʻonā NMR o kahi peptide mai ka mdm-2 paʻa paʻa o ka p53 protein i koho cytotoxic i nā maʻi kanesa.. Biochemistry 2004, 43 (7), 1854-1861. DOI: 10.1021/bi035718g Mai NLM Medline.

(3) Sookraj, K. A.; Bowne, Ua ʻōlelo ʻo W. B.; Adler, V.; Sarafraz-Yazdi, E.; Michl, J.; Pincus, M. R. ʻO ka peptide anti-cancer, PNC-27, hoʻoulu i ka lysis cell tumor e like me ka peptide paʻa. ʻO ka lāʻau lapaʻau ʻo Cancer Chemother 2010, 66 (2), 325-331. DOI: 10.1007/s00280-009-1166-7 Mai NLM Medline.

(4) ʻO Thad, A.; Lewis, L.; Goldstein, E.; Aggarwal, A.; ʻO Khalil, M.; Steele, L.; Pōlani, B.; Seydafkan, S.; Bluth, M. H.; Ward, K. A.; et al. ʻO ka huli ʻana i ka membrane HDM-2 e PNC-27 e hoʻoulu ai i ka necrosis i loko o nā maʻi leukemia akā ʻaʻole i loko o nā cell hematopoietic maʻamau.. Anticancer Res 2020, 40 (9), 4857-4867. DOI: 10.21873/anticanres.14488 Mai NLM Medline.

(5) ʻO Wang, H.; ʻO Zhao, D.; ʻO Nguyen, L. X.; ʻO Wu, H.; Li, L.; ʻO Dong, D.; Troadec, E.; ʻO Zhu, Y.; Hoang, ʻO D. H.; Stein, A. S.; et al. Ke kuhi nei i ka membrane cell HDM2: ʻO kahi ala lapaʻau hou no ka leukemia myeloid acute. Leukemia 2020, 34 (1), 75-86. DOI: 10.1038/s41375-019-0522-9 Mai NLM Medline.

Kaʻina:

H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg

CAS:

1159861-00-3

M.W:

4031.7990g/mol

Home Huli Whatsapp Nā lawelawe Huahana